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Abstract: Altered intestinal microbiota is associated with systemic and intestinal diseases, such as
inflammatory bowel disease (IBD). Dysbiotic microbiota with enhanced proinflammatory capacity is
characterized by depletion of anaerobic commensals, increased proportion of facultatively anaerobic
bacteria, as well as reduced diversity and stability. In this study, we developed a high-throughput
in vitro screening assay to isolate intestinal commensal bacteria with anti-inflammatory capacity
from a healthy fecal microbiota transplantation donor. Freshly isolated gut bacteria were screened
for their capacity to attenuate Escherichia coli lipopolysaccharide (LPS)-induced interleukin 8 (IL-8)
release from HT-29 cells. The screen yielded a number of Bacteroides and Parabacteroides isolates,
which were identified as P. distasonis, B. caccae, B. intestinalis, B. uniformis, B. fragilis, B. vulgatus and
B. ovatus using whole genome sequencing. We observed that a cell-cell contact with the epithelium
was not necessary to alleviate in vitro inflammation as spent culture media from the isolates were also
effective and the anti-inflammatory action did not correlate with the enterocyte adherence capacity
of the isolates. The anti-inflammatory isolates also exerted enterocyte monolayer reinforcing action
and lacked essential genes to synthetize hexa-acylated, proinflammatory lipid A, part of LPS. Yet,
the anti-inflammatory effector molecules remain to be identified. The Bacteroides strains isolated and
characterized in this study have potential to be used as so-called next-generation probiotics.
Keywords: bacteroides; gut homeostasis; host-microbe interactions; immunomodulation; LPS;
next-generation probiotics
1. Introduction
The human intestine harbors a complex bacterial ecosystem of which 90% of the species belong
to the phyla Firmicutes and Bacteroidetes [1–3]. Most individuals carry approximately 200 different
bacterial species with varying abundance in their gastrointestinal tract but only around 30% of the
species, the so-called common core microbiota, are shared between subjects [4,5]. Together with
hosts’ genetic and immunological background, environmental factors such as diet, use of antibiotics
and other medication and hygienic conditions affect the gut microbiota composition [6]. Dysbiotic,
unbalanced intestinal microbiota composition with enhanced proinflammatory capacity is characterized
by reduced species richness and diversity as well as reduced microbial stability [7]. Alterations in the
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abundance of health-associated, short-chain fatty acid-producing Firmicutes and proinflammatory,
lipopolysaccharide-(LPS-)containing pathobionts, such as gamma-Proteobacteria, have been linked
to dysbiosis [8]. Moreover, loss of intestinal immune homeostasis and barrier function is associated
with systemic and intestinal diseases, such as inflammatory bowel disease (IBD) and irritable bowel
syndrome (IBS) [9]. Several studies have shown that IBD patients have decreased abundance of
mucosal or fecal Bacteroides in comparison to healthy subjects [10–12].
Manipulation of the gut microbiota towards a more balanced and optimal microbial community
to promote human health has received increasing interest in recent years. In addition to traditional
probiotics and prebiotics [13], new therapeutic approaches ranging from total microbiota manipulation
by fecal microbiota transplantation (FMT, [14]) to narrow-spectrum microbiota manipulation by
targeted inhibition of metabolic pathways in a specific bacterial group [15] are being investigated.
The great success of FMT in treating recurrent Clostridioides difficile infection (rCDI) and promising
findings for several other conditions [14] together with studies on microbiota dysbiosis have paved
the way for so-called next generation probiotics and the development of bacteriotherapy [8]. In IBD,
where the treatment success of FMT has been variable [16,17], using defined bacterial communities as
a potent bacteriotherapy could provide more consistent efficacy compared to FMT which has significant
variation between donors [18]. Indeed, in a murine model of IBD, treatment with triple Bacteroides
strain combination, and specifically B. ovatus, decreased inflammation and was more effective at
reducing colitis than traditional FMT [19]. Recently, the U.S. Food and Drug Administration (FDA)
approved an Investigational New Drug (IND) application concerning the safety and efficacy of B. ovatus,
B. thetaiotaomicron and B. vulgatus as a treatment for rCDI [19]. In a study about encapsulated delivery
of FMT, Bacteroides and Parabacteroides were among the species that primarily contributed to the donor
engraftment, potentially serving as keystone species in maintaining donor-like microbiota [20].
Bacteroidetes is the second largest phylum after Firmicutes in the healthy adult human gut [1–3]
and its relative proportion of the total microbiota is higher in mucosa than in feces [21]. Genus Bacteroides,
accounting for approximately 30% of the intestinal microbiota, contains most predominant species
within the Bacteroidales order [22]. Bacteroides spp. are equipped with different mechanisms in order
to adapt to the harsh environment of the intestine, such as metabolizing many diet- and host-derived
polysaccharides, oxygen toleration using cytochrome bd oxidase, and vast expression of cell surface
structures [23]. Bacteroides species include many important opportunistic pathogens, but as essential
members of a balanced microbiota they are considered to be health-maintaining. This is due to their
ability to reinforce the epithelial barrier and ameliorate inflammation by producing anti-inflammatory
molecules such as polysaccharide A (PSA), sphingolipids and outer membrane vesicles (OMV) for
the transport of aforementioned molecules to the epithelium via the thick mucus layer [24–27]. Thus,
Bacteroides spp. could be promising bacteriotherapeutic candidates for use in clinical and nutritional
applications, but more research on this matter is needed. Safety assessment of strains needs to be
thorough because some representatives of the genus are also important opportunistic pathogens.
In this study, we aimed to isolate intestinal commensal bacteria with anti-inflammatory capacity
from a healthy FMT donor and set up a high-throughput in vitro screening assay for this purpose. In the
screening, we assessed the potential of freshly isolated gut bacteria to attenuate LPS-induced interleukin
8 (IL-8) release from enterocytes i.e., to alleviate inflammatory reaction caused by LPS. The promising
isolates from the screen were purified and after a thorough validation of their anti-inflammatory
capacity, they were tentatively identified by partial 16S rRNA gene sequencing. Isolates representing
Bacteroides and Parabacteroides spp. were selected for further studies, which included whole genome
sequencing and assessment of adhesive and epithelium reinforcing properties.
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2. Materials and Methods
2.1. Bacterial Isolation and Tentative Identification
Feces from a healthy pre-screened adult, who acted as a donor for FMT, were freeze-stored as
a saline-10% glycerol solution at −80 ◦C using a protocol that is successfully used for fecal banking for
FMT [28]. The preparation was done under ambient air and the sample was frozen within 1.5 h from
defecation. The use of the donor was approved by the Ethics Committee of Hospital District of Helsinki
and Uusimaa Finland (DnroHUS124/13/03/01/11). The donor, described in a previous study [21],
provided a written informed consent. The donor was a healthy Finnish female, aged 42 years, with
a normal body mass index (BMI < 25), no gastrointestinal symptoms and no antibiotic use for the
past 6 months. The donor passed all the screening tests for fecal donors [28]. All experiments were
carried out in accordance with relevant guidelines and regulations. The frozen fecal solution was
thawed in 4–5 hours, serially diluted in phosphate-buffered saline (PBS) and cultivated on Brucella
agar (Sigma Aldrich, St. Louis, MO, USA) supplemented with 5% sheep blood (Bio Karjalohja Oy,
Karjalohja, Finland), Gifu anaerobic medium (GAM; Nissui Pharmaceutical Co., Ltd., Tokyo, Japan)
and reinforced clostridial medium (RCM; Becton Dickinson, Sparks, USA) under anaerobic conditions
using an anaerobic chamber containing 85% N2, 10% CO2, and 5% H2 at 37 ◦C (Concept Plus anaerobic
workstation, Ruskinn Technology Ltd., Bridgend, UK). The anaerobic chamber automatically purged
gas inside the chamber when needed. Palladium catalyst inside the chamber scavenged any residual O2
and anaerobic color indicator strips were used to verify anaerobic conditions. All media were reduced
in the anaerobic atmosphere inside the anaerobic workstation for 24 hours before the cultivation.
Separate colonies were picked over 72 hours and re-streaked on new agar plates. Each isolate was
cultivated in appropriate broth or on agar, i.e., the medium used originally to isolate the bacterium,
for the preliminary screening of attenuation capacity. Frozen stocks were prepared from the same
bacterial culture and stored at −80 ◦C. The screening of anti-inflammatory isolates (described in detail
in paragraph 2.3) was first carried out in 96-well microtiter plates using one replicate due to the large
number of isolates. Next, the screening was repeated for potentially positive isolates using three
replicates. The potentially positive isolates were re-streaked on agar plates until pure cultures were
obtained. The pure cultures were subjected to Gram-staining and microscopy to evaluate the purity
of the cultures. Partial 16S rRNA gene sequencing was used for tentative identification, for which
bacterial mass from each isolate was resuspended in TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 8)
and heated to 95 ◦C for 15 min to break the cells. The resulting cell lysates were used as the template in
PCR amplification of the partial 16S rRNA gene using 27F DegL (5′-AGR GTT YGA TYM TGG CTC
AG-3′) forward and Pd (5′-GTA TTA CCG CGG CTG CTG-3′) reverse primers. Sanger sequencing
of the PCR product using the forward primer was carried out in the Institute of Biotechnology core
facility, University of Helsinki. The partial 16S rRNA gene sequences were compared to NCBI 16S
ribosomal RNA sequences database using BLASTn to acquire tentative identification at the genus level.
2.2. Epithelial Cell Lines
The human colonic epithelial cell lines Caco-2 (ACC 169) and HT-29 (ACC 299) were acquired from
German Collection of Microorganisms and Cell Cultures (DSMZ) and grown at 37 ◦C in an incubator
under oxic atmosphere with 5% CO2. Cells were passaged after reaching 80% confluence using
HyClone HyQTase (GE Healthcare Life Sciences, Marlborough, MA, USA) to detach the cells and
passage numbers up to 28 were used in the experiments. Caco-2 cells were cultivated in RPMI 1640
medium (Sigma-Aldrich, USA) supplemented with heat-inactivated (30 min at 56 ◦C) fetal bovine
serum (20%; FBS; Gibco, UK), nonessential amino acids (1%, NEAA; Lonza, Bornem, Belgium), 15 mM
HEPES (Lonza, Belgium), 100 U mL−1 penicillin and streptomycin (PEST; Lonza, Belgium) and 2 mM
L-glutamine (Lonza, Belgium). HT-29 cells were grown in McCoy 5A (Lonza, Belgium) medium
containing 10% FBS and 100 U mL−1 PEST.
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2.3. Screening of Anti-Inflammatory Capacity of the Isolates
The capacity of bacterial isolates to attenuate LPS-induced IL-8 production in HT-29 cells was
measured as previously described [29], but the assay was adjusted to high-throughput 96-well plate
format. HT-29 cells were seeded 10,000 cells per well onto 96-well microplates for the attenuation assay.
Broth cultures of bacteria were washed once with McCoy 5A medium supplemented with FBS (10%)
and resuspended in the same medium. The bacterial mass of isolates grown on solid agar was collected
and resuspended in McCoy 5A medium with FBS supplement. The bacterial suspensions were adjusted
to OD600nm 0.25 corresponding approximately to 108 cells/mL and 100 µl of this suspension was added
onto 8 days post-plating HT-29 cells and incubated at 37 ◦C for 1 hour under oxic atmosphere with 5%
CO2. The bacterial concentration used in the experiments (final concentration of 107 cells/mL) was
considered biologically relevant for in vitro assays as the amount of Bacteroides spp. in the intestine
could theoretically be 5 × 109/mL up to 3 × 1010/mL. The abundance of Bacteroidetes in a healthy
microbiota has a lot of inter-individual variance, but in general it is up to 30% in feces and the bacterial
content in the stool is approximately 1011/g of feces [30]. The percentage of Bacteroides spp. in the
feces of the donor used in this study was approximately 5% [21]. McCoy 5A medium containing 10%
FBS was used as the control. Afterwards, the bacterial suspensions were removed from the HT-29
monolayer and 200 µl McCoy 5A medium with 1 ng/mL of E. coli LPS (Sigma Aldrich, USA) was
added. After a 4-hour incubation with LPS, supernatants were collected and IL-8 levels were measured
by using an ELISA assay (BD OptEIATM Set, San Diego, USA). The use of aerobic conditions with
increased CO2 (5%) in the screening assay using anaerobic bacteria was considered appropriate due to
the short activation time i.e., 1-hour incubation on the HT-29 cells before removing the bacterial cells
and adding LPS. It is also known that anaerobic bacteria can tolerate oxygen for 1 hour up to 72 hours
depending on the species [31], and Bacteroides spp. sustain aerobic conditions better compared to other
anaerobic gut bacteria [32].
The IL-8 levels were calculated using four parametric logistic curves and the effect of the isolates
on the LPS-induced IL-8 production was assessed by comparing the levels to that of the LPS control.
In the first screening only one replicate (well) per isolate was used and criteria for positive isolate was
a reduction of IL-8 level lower than the LPS control. No statistical testing was applied as only one
replicate per isolate was tested. In the second round of screening, three replicates (wells) per isolate
were used and the average result of three replicates per sample was compared to the LPS control by
using a t-test, and all isolates that showed a significant (p < 0.05) reduction in the IL-8-levels as compared
to the control were selected for further testing. No secondary statistical analysis by using a post-hoc
test against false positives was taken because all isolates would subsequently undergo validation by
using biological testing, and therefore loose statistical criteria were applied at the screening stage.
Finally, the attenuation assay was repeated with the purified, potentially positive isolates several times.
IL-8 assay was only performed using the HT-29 cell line due to defects in the TLR4 signaling of Caco-2
cell line which caused unresponsiveness to LPS stimulation [33–35].
The spent medium attenuation assay was carried out similarly as described above. The positive,
anti-inflammatory action-exerting isolates were all grown in GAM broth under anaerobic conditions
and the OD600nm was adjusted to 1.0. The adjusted bacterial suspensions were centrifuged (10,000 RPM,
3 min.) to pellet the cells and the supernatants were filtered with 0.2 µm filter to remove any remaining
bacterial cells. The supernatants were diluted to 1:4 and 1:2 using McCoy 5A medium supplemented
with FBS (10%). GAM and McCoy 5A were included in the assay as controls.
2.4. Bacterial Adhesion to Cell Lines and Mucus
The adherence of bacterial isolates to Caco-2 and HT-29 cell lines (8 days post-plating) and mucus
was studied as described previously [36,37]. Four technical replicates (parallel wells) were used in
each experiment. Bacteria were grown in an appropriate medium supplemented with 10 µL mL−1
of [6′-3H]thymidine (17,6 Ci mmol−1, Perkin Elmer, Waltham, USA) to metabolically radiolabel the
cells. All isolates within the same species were grown identically and tested for adhesion in the
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same experiment. For epithelial adherence assay, HT-29 and Caco-2 cells were seeded 10,000 cells per
well onto 96-well microplates. To assess the adherence to intestinal mucus (separate assay from the
cell lines), porcine mucus (Sigma-Aldrich, 50 µg well-1 in PBS) was allowed to adsorb to Maxisorp
microtiter plate wells overnight at 4 ◦C. [3H]Thymidine-labelled bacterial cells were washed with
an appropriate medium (McCoy 5A for HT-29 cells, RPMI 1640 for Caco-2 cells and PBS for the mucus
assay) without supplements and adjusted to OD600nm 0.25, which corresponded to approximately
108 cells/mL. The bacterial suspensions were incubated for one hour on the epithelial cell monolayer
or mucus at 37 ◦C in a CO2 incubator, followed by washing three times to remove the non-adherent
cells. Adhered bacteria were lysed with 1% SDS-0.1 M NaOH and radioactivity was measured with
a liquid scintillator (Wallac Winspectral 1414, Perkin Elmer, Waltham, MA, USA). The percentage of
bound bacteria was calculated relative to the radioactivity of the bacterial suspension initially added to
the wells.
2.5. Effect of Bacteria on Epithelial Integrity
Caco-2 cells undergo enterocytic differentiation and express intercellular junctional complexes,
making them a suitable model to measure transepithelial electrical resistance (TER) as an indicator of
the monolayer integrity [38–40]. The impact of bacterial isolates on the TER of Caco-2 monolayer was
studied as previously described [29,37]. Briefly, 50,000 Caco-2 cells were seeded on PET inserts with
a pore size of 3 um (Sarstedt, Nümbrecht, Germany) and grown for 8 days. The medium in the well
was changed every 3 days. After 8 days Caco-2 cells form a monolayer, are partially differentiated
and are in an appropriate growth phase to measure the development of transepithelial resistance and
how it is affected by external factors [36,37]. E. coli TOP10 has been shown to adversely affect the
monolayer integrity and was used as a negative control in the experiments [37]. Bacterial cells were
washed once with RPMI medium and 100 µL of bacterial suspension adjusted to OD600 of 0.25 was
added to the inserts after the time 0 measurement. The TER measurements were carried out using
an EVOM epithelial voltohmmeter with an electrode (World Precision Instruments, UK). The inserts
containing the bacterial isolates were incubated at 37 ◦C in a CO2 incubator and the TER was measured
again after 24 hours. The blank resistance (measurement at time point 0) was subtracted from the
measurements made after 24 hours of incubation, and the unit area resistance (Ω cm2) was calculated
by multiplying the tissue resistance values by surface area of the filter membrane. The change in TER
over 24 hours was calculated by comparing the samples to the medium control.
2.6. Genome Sequencing
Genomic DNA was extracted from bacterial cell pellets using the DNeasy Blood and Tissue Kit
(Qiagen, Hilden, Germany) following the manufacturer’s protocol for Gram-negative bacteria. DNA
was fragmented using a Q800R2 Sonicator (QSonica, Newtown, CT, USA) to approximately 500 bp,
and genome libraries were prepared for paired end sequencing using the NEBNext® Ultra™ II Kit
(New England Biolabs, Ipswich, MA, USA) and quantified using the Library Quantification Kit (KAPA
Biosystems, Waltham, MA, USA). Libraries were pooled in equimolar amounts and sequenced on
the MiSeq (Illumina, Inc., San Diego, CA, USA). Read data were deposited in the NCBI SRA under
BioProject PRJNA575760. Short read data were assembled using unmanned genome assembly pipeline
(UGAP; https://github.com/jasonsahl/UGAP), which uses the SPAdes genome assembler. The species
of each genome was identified using Kraken (PMID: 24580807) and confirmed by its placement in the
phylogenetic trees generated for each species (see below).
Whole genome single nucleotide polymorphism (SNP) typing (WGST) was used to determine
whether any genomes from this study had high identity to previously published genomes. For WGST,
SNP matrices to identify point mutations among the isolates (and thus infer strain relatedness) were
generated with NASP [41], in which reads were aligned to a publicly available assembly using
BWA [42]. SNPs were called with Genome Analysis Toolkit (GATK) [43] and were only included in
further analyses if they were a) present in all samples, b) covered by≥10X depth with≥90% consensus in
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each sample, and c) not in any duplicated regions in the reference genome as identified by NUCmer [44].
The resulting SNP matrix comprised the core genome common to all samples in the analysis. Maximum
likelihood phylogenetic analyses were performed with IQ-TREE [45]. Maximum parsimony analyses
were performed with MEGA v7.0 [46] or RAxML (version 8.2.10, [47]).
2.7. Statistical Analysis
All the adhesion and attenuation experiments were done using three to four technical replicates
depending on the assay and repeated two to four times (biological replicates) to confirm the results.
Different cultures of bacteria and different passages of cell lines were used in the separate experiments.
A two-sample t-test was used to determine significant differences between a sample and the control.
Homoscedasticity testing was performed with Levene’s test to identify equal or unequal variances.
Point biserial correlation was calculated between the attenuation capacity as the dichotomous variable
and adhesion or TER as the continuous variable. All statistical analyses were carried out with IBM
SPSS Statistics program version 21.0 (IBM Corporation, New York, NY, USA) with a p-value of <0.05
considered statistically significant.
2.8. Data Availability
Whole genome sequence read data were deposited in the NCBI SRA under
BioProject PRJNA575760.
3. Results
3.1. A High-Throughput Screening Method
In this study, we developed a high-throughput assay to screen commensal bacteria exerting
anti-inflammatory action in the human gastrointestinal tract. First, bacteria from fecal material of
a pre-screened, healthy FMT donor was cultivated on GAM (Gifu anaerobic medium), RCM (reinforced
clostridial medium) and Brucella agar under anaerobic conditions and 600 bacterial isolates were picked
during 72 hours of incubation (Figure 1). The screening of anti-inflammatory capacity was performed
by pre-treating the HT-29 cell line first with the bacterial isolates and then with E. coli LPS, which induces
an IL-8 release from the enterocyte cell line. In LPS-induced HT-29 cells that were pre-treated with
an isolated bacterium as compared to controls without pre-treatment (i.e., LPS-induction alone),
a decrease in the produced IL-8 levels was considered as an indication of anti-inflammatory capacity.
In the first screening round, during which we tested 600 isolates with one replicate (well) per isolate,
170 isolates (28% of all the isolates) reduced the IL-8 levels as compared to the LPS control. The second
screen using several replicates per isolate yielded 38 positive isolates that significantly reduced
the IL-8 release from HT-29 cells. The positive isolates were purified and tentatively identified at
the genus level by using 16S rRNA gene sequencing. Over 75% of the isolates belonged to the
Bacteroidales order, including genera Parabacteroides (6 isolates), Bacteroides (22 isolates) and Odoribacter
(1 isolate). The remaining isolates were identified as Cutibacterium (3 isolates), Streptococcus (1 isolate)
and Bifidobacterium (5 isolates). We focused our further studies on the Parabacteroides and Bacteroides
isolates, which formed a major part of the bacterial isolates and are specifically associated with the
restoration of mucosal microbiota after FMT [20,21]. Moreover, these species have shown interesting
immunomodulatory capacities in previous studies [12,19,48–51].
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Figure 1. The high-throughput approach to screen for anti-inflammatory bacteria and the outcomes
from different steps.
3.2. Whole Genome Sequencing (WGS)
The genomes of 28 Parabacteroides and Bacteroides isolates were obtained using whole genome
sequencing (WGS) and identified on a species level with Kraken (PMID: 24580807; Supplementary Table
S1). All six Parabacteroides isolates had a 5.0 Mb assembled genome size and 45.1% GC content and
were confirmed as Parabacteroides distasonis (Pd). The Bacteroides isolates were identified as B. caccae (Bc,
3 isolates), B. fragilis (Bf), B. intestinalis (Bi, 3 isolates), B. uniformis (Bu), B. vulgatus (Bv, 5 isolates) and
B. ovatus (Bo, 9 isolates) with assembled genome size and GC content ranging between 4.4–6.9 Mb and
41.9–46.5%. In addition, the parsimony trees based on whole genome single nucleotide polymorphism
(SNP) typing (WGST) indicated a close relatedness of the isolates within a species (Figure 2 and
Supplementary Figure S1). Furthermore, SNP typing using NASP revealed that the isolates belonging
to the same species had less than 10 genomic SNP differences to each other, but more than 10,000 SNP
differences on average to database strains (Supplementary Excel file, Figure 2 and Figure S1). Thus,
all isolates within the same species are most likely representatives of the same strain or at least have
a common origin.
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Figure 2. Estimates of evolutionary divergence by whole genome single nucleotide polymorphism
(SNP) typing (WGST) (number of SNP differences per sequence) between the isolates belonging to the
same species and previously published genomes (NCBI database). Panel (A) is P. distasonis (Pd) and
panel (B) is B. ovatus (Bo).
3.3. Anti-Inflammatory Properties
Next, we assessed the robustness of the immunomodulatory attributes among the 28 isolates,
that is their ability to consistently alleviate LPS-induced IL-8 release from one experiment to another.
The assay was repeated three or more times with all the purified and genome-sequenced bacterial
isolates. Isolates that significantly (p ≤ 0.05) decreased IL-8 release in at least three individual
experiments and in the majority of independent experiments (for example, in three out of five
experiments) were considered to have attenuation competence (Table 1). All B. caccae, B. intestinalis,
B. uniformis and B. vulgatus isolates repeatedly showed the ability to significantly decrease LPS-induced
IL-8 release from HT-29 cells as compared to the LPS control. Among B. caccae, B. intestinalis and
B. vulgatus isolates, the attenuation capacity seemed very stable and consistent across the isolates of the
same species. The B. fragilis isolate could not be verified to exert anti-inflammatory action as it did not
affect IL-8 production in LPS-induced HT-29 cells. Interestingly, only three out of six P. distasonis and
two B. ovatus isolates were confirmed to exert anti-inflammatory action in vitro, suggesting that the
attenuation competence is not a robust trait among these isolates, which are derived from a common
ancestor strain and seem to be prone to loosing or inconstantly expressing the trait. Importantly,
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the non-attenuating isolates, where no significant (p ≥ 0.05) difference to the LPS control was noticed,
did not stimulate a pro-inflammatory reaction in the HT-29 cell line either.
Table 1. The capacity of Bacteroides and Parabacteroides isolates to attenuate lipopolysaccharide
(LPS)-induced IL-8 release from HT-29 cell line.
Isolate
Significant IL-8 Decrease */
Total Number of Attenuation
Experiments
% Decrease in IL-8 Release as
Compared to the LPS Control
Attenuation
Competence #
Pd1 1/4 7–53 -
Pd2 4/5 35–61 +
Pd3 3/3 27–39 +
Pd4 4/6 23–59 +
Pd5 0/3 0–11 -
Pd6 0/3 15–23 -
Bc1 4/6 12–44 +
Bc2 3/4 21–46 +
Bc3 3/5 33–48 +
Bf 0/3 1–34 -
Bi1 3/3 21–72 +
Bi2 3/4 25–66 +
Bi3 3/4 27–51 +
Bu 4/6 34–59 +
Bv1 3/4 26–39 +
Bv2 3/3 23–36 +
Bv3 5/9 39–59 +
Bv4 3/3 25–40 +
Bv5 3/3 41–55 +
Bo1 2/5 5–58 -
Bo2 4/8 0–39 -
Bo3 4/6 30–50 +
Bo4 3/4 35–57 +
Bo5 3/7 0–39 -
Bo6 0/3 17–26 -
Bo7 3/7 0–28 -
Bo8 2/5 0–54 -
Bo9 1/5 0–45 -
* Significant (p < 0.05) decrease in IL-8 release as compared to the control, i.e., LPS stimulation without a prior
exposure to the studied isolate. #no attenuation or seldomly detected (−), attenuation constantly detected (+). Pd
= P. distasonis, Bc = B. caccae, Bf = B. fragilis, Bi = B. intestinalis, Bu = B. uniformis, Bv = B. vulgatus, Bo = B. ovatus.
Numbers 1–9 refer to the specific isolate. # Isolates that significantly (p ≤ 0.05) decreased IL-8 release in at least three
independent experiments and in majority of experiments were considered to have attenuation competence (+).
3.4. Mucosal Adherence of the Isolates
All B. ovatus isolates were clearly non-adherent to Caco-2 and HT-29 cell lines as well as to mucus
since their relative adherence percentage (measured as the proportion of adhered bacteria compared
to the total added bacteria) was below 1%, which can be considered unspecific binding comparable
to background levels (Figure 3). The three B. caccae isolates adhered only to mucus. Among the
P. distasonis strains, only Pd1 was adherent while the binding capacity of the other P. distasonis isolates
was close to the background level. Conversely, all B. intestinalis, B. uniformis and B. fragilis isolates
could adhere to Caco-2, HT-29 and mucus with a relative adherence level of approximately 2–5%.
We found no correlation between the isolates’ capacities to adhere to HT-29 cells and to attenuate
LPS-induced IL-8 release from the enterocyte cell line (Point biseral correlation, rpb = 0.084, p = 0.670)
and thus the anti-inflammatory action does not seem to require a firm cell-cell attachment between
bacteria and intestinal epithelial cells.
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Figure 3. Adherence of the isolates to Caco-2 and HT-29 cell lines and to intestinal mucus. Pd =
P. distasonis, Bc = B. caccae, Bf = B. fragilis, Bi = B. intestinalis, Bu = B. uniformis, Bv = B. vulgatus, Bo =
B. ovatus. Numbers 1–9 refer to the specific isolate. Symbol + indicates isolate’s capacity to attenuate
LPS-induced IL-8 release from HT-29 cell line.
Subsequently, we assessed the anti-inflammatory action of cell-free spent medium from the
bacterial cultures by using the culture supernatant in the attenuation assay (Figure 4). Pre-incubation
of HT-29 cells with 1:2 (50%) or 1:4 (25%) diluted spent culture medium from the isolates significantly
decreased IL-8 release during the subsequent LPS stimulation as compared to the LPS and unspent
bacterial growth medium controls, thus confirming that a firm cell-cell attachment between bacteria
and epithelial cells is not necessary to exert the anti-inflammatory effect.
Figure 4. The attenuation capacity of the isolates using spent medium i.e., culture supernatant.
Gifu anaerobic medium (GAM) and McCoy 5A media as well as only LPS were used as controls. LPS
control represents 100% IL-8 release from HT-29 cells. 12 and
1
4 dilutions of spent media were used in
the assay. Pd = P. distasonis, Bc = B. caccae, Bf = B. fragilis, Bi = B. intestinalis, Bu = B. uniformis, Bv =
B. vulgatus, Bo = B. ovatus. Numbers 1–9 refers to certain isolates.
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3.5. Epithelium Reinforcing Action
Next, we studied the epithelium reinforcing properties of the isolates that showed
anti-inflammatory properties. The ability of the isolates to enhance Caco-2 monolayer integrity
was assessed by co-culturing the enterocyte cell line with the bacterial isolates and using transepithelial
electrical resistance measurements to address maintenance or improvement of the barrier function (TER,
Figure 5). A commercial E. coli laboratory strain was used as a negative control as it adversely affects
the integrity of the monolayer [37]. After eight days of post-plating the Caco-2 monolayer showed
a baseline TER of 319 ± 16 Ω. Most isolates that displayed the capacity to attenuate LPS-induced IL-8
release also showed the capacity to reinforce epithelial integrity in vitro (Figure 5). As an exception,
the three P. distasonis isolates did not induce significant changes in TER values as compared to the
monolayer treated with only medium. In other words, the isolates did not reinforce nor compromise
the epithelial integrity of the monolayer. B. vulgatus isolates improved the monolayer integrity the
most effectively. Among the isolates, the capacity to attenuate LPS-induced IL-8 production correlated
positively with the ability to reinforce the integrity of Caco-2 monolayer (rpb = 0.397, p = 0.061).
However, there was no correlation between the adherence level of the isolates to Caco-2 cells and their
ability to reinforce the enterocyte monolayer integrity (r = 0.109, p = 0.620).
Figure 5. The effect of isolates on transepithelial electrical resistance (TER) of Caco-2 monolayer. E. coli
was used as a negative control. Results are shown as the mean of TER value change (Ω/cm2) in 24 hours
and standard deviation of three technical replicates (parallel wells). An asterisk indicates significantly
different (p < 0.05) value as compared to the untreated Caco-2 monolayers (medium control). * p < 0.05,
** p < 0.01, *** p < 0.001. Pd = P. distasonis, Bc = B. caccae, Bi = B. intestinalis, Bu = B. uniformis, Bv =
B. vulgatus, Bo = B. ovatus. Numbers 1–9 refer to the specific isolate.
3.6. Genes Involved in Host-Microbe Interactions of Bacteroides spp.
We screened the assembled genomic data of the isolates for genes known to have an important role
in the host-microbe interactions of Bacteroides spp. First, we searched the genomes of the isolates for
genes that encode enzymes for Kdo2-lipid A modification using BLAST (Basic Local Alignment Search
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Tool, blastp algorithm). All the genomes of Parabacteroides and Bacteroides isolates carried the genes
encoding LpxA-LpxK for the Kdo2-lipid A moiety synthesis but lacked the genes for LpxL and LpxM
acyltransferases. LpxL and LpxM are needed for adding the secondary acyl chains (hexa-acylation) into
lipid A yielding a highly pro-inflammatory LPS structure typical for gamma-Proteobacteria including
E. coli [52,53]. Inability to hexa-acylate lipid A potentially explains why the Parabacteroides and
Bacteroides isolates, despite being LPS-carrying organisms, did not evoke pro-inflammatory responses
in enterocytes.
As we found the attenuation capacity to be independent of the cell-cell contact and possibly
mediated through secreted effector molecules such as zwitterionic capsular polysaccharides (ZPS,
e.g., Polysaccharide A of B. fragilis) transported in OMVs, we searched the genomes for wcfR gene
homologues encoding for a protein that is needed in the synthesis of ATTGal-ZPS proteins. A match to
the wcfR gene was found in the genome of the B. fragilis isolate (90.9% nucleotide identity, data not
shown) but not in the other isolates and thus could not explain their anti-inflammatory properties.
We also searched the genomes of the Parabacteroides and Bacteroides isolates for a gene encoding
serine palmitoyltransferase (SPT, BT_0870), an enzyme mediating the synthesis of sphingolipids,
which were recently reported to mediate the Bacteroides-host interaction in maintaining homeostasis
and symbiosis in the gut [24]. A match of 87%, 88% and 76% nucleotide identity to the spt gene was
found in the genomes of all B. caccae, B. ovatus and B. intestinalis isolates, respectively. A 73% match to
spt was also found in the genome of B. fragilis. No significant similarity was observed in P. distasonis,
B. uniformis or B. vulgatus genomes concerning the spt gene. Thus, the presence or absence of the
spt gene did not explain the anti-inflammatory or epithelium re-enforcing capacities of the isolates.
Overall, we could not confirm across all our isolates the presence of wcfR or spt, which have been
previously linked with the anti-inflammatory properties of Bacteroides spp. Thus, these genes do not
seem to be universally distributed among Bacteroides spp. and the properties encoded by them can be
suspected to mediate anti-inflammatory properties in some but not all strains.
4. Discussion
In this study we developed a high-throughput method to screen gut commensals with
anti-inflammatory potential and retrieved in pure cultures 38 isolates, the majority of which were
representatives of the genera Bacteroides and Parabacteroides. We acknowledge that the screening in
our study was limited to those bacteria which can be grown under the culture conditions applied,
but there are multiple species present in the human gut microbiota that can exert anti-inflammatory
action, including also potentially novel species [8]. Bacteroides and closely related genera are highly
abundant commensals in the human gut and their decreased abundance has been linked with intestinal
inflammation e.g., in IBD and cystic fibrosis patients [11,12,54,55], and their higher abundance,
specifically B. fragilis and B. finegoldii, was linked to a donor stool batch that was effective in keeping
ulcerative colitis (UC) in remission after FMT [56]. Furthermore, several mice studies have recently
demonstrated the potential of Bacteroides spp. in ameliorating intestinal inflammation [19,48,51,57,58].
Thus, the potential of Bacteroides spp. and closely related bacteria to alleviate inflammation in vitro
seems to correspond to their in vivo action.
Based on the WGS results, our screened isolates from an FMT donor were identified as P. distasonis,
B. caccae, B. fragilis, B. intestinalis, B. uniformis, B. vulgatus and B. ovatus, which are all typical gut
commensals in the human intestinal tract. SNP typing revealed that isolates belonging to the same
species are representatives of the same strain or at least have a common ancestor. Our results and
conclusions are in line with the previous observations that single strains typically dominate most
species in the gut microbiota [59]. Concerning Bacteroides spp., even in the case of multiple strains
within a species co-existing, the relative abundance of the main strain was 87% and 91% for B. uniformis
and B. vulgatus, respectively [59]. Notably, Bacteroides and Parabacteroides species are remarkably
genetically consistent with only on average 0.45% of nucleotide variants between strains, which may
hamper strain differentiation. On the other hand, with more genetically plastic gut commensals such
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as Prevotella, the variation reaches to 2.44% [59]. However, our isolates had less than 10 SNP differences
with each other within the same species and thus we considered them to have a common ancestor or
represent the same strain.
The in vitro capacity to attenuate inflammation was shown to be consistent among the isolated
strains within the species B. caccae, B. instestinalis and B. vulgatus as all the isolates significantly decreased
the cytokine IL-8 levels in an LPS-induced enterocyte cell line. In the case of P. distasonis and B. ovatus,
the attenuation competence varied among the isolates despite them being genomically very similar,
and the reason for this remains to be studied in detail. Despite consistency in the cultivation conditions,
we cannot rule out variations in gene expression in different cultivation batches. Another possibility is
that some of the isolates have lost their ability to produce the needed effector molecules, which remains
to be studied with more detailed comparative genomic approaches.
Three out of the six P. distasonis isolates were able to attenuate inflammation in our in vitro
model, although they did not enhance the epithelial integrity in the Caco-2 monolayer. In general,
the anti-inflammatory attributes among gut commensals are highly strain-specific, but P. distasonis
strains with anti-inflammatory properties have been described previously. A recent study showed that
the membrane fraction of P. distasonis caused a 55% and 29% reduction in IL-8 production in E. coli LPS
induced HT-29 and SW480 cell lines, respectively [48]. P. distasonis crude lysate and membrane fraction
have also been shown to decrease the disease severity in a dextran sulfate sodium (DSS)-induced colitis
murine model [60].
We did not find any correlation between the isolates’ ability to adhere to intestinal epithelium
and to attenuate LPS-induced inflammation or to strengthen the epithelial monolayer integrity. Yet,
we observed that a firm cell-cell attachment between bacteria and enterocytes was not necessary for the
isolated strains to exert their anti-inflammatory activity as their culture supernatants also attenuated
LPS-induced IL-8 release from the HT-29 cell line. We did not address the bacterial cell viability
during the incubation time with the HT-29 cells, but as bacterial supernatants were also found to exert
the anti-inflammatory action, it seems that the presence of effector molecules rather than bacterial
viability per se is needed for the activity. Secretion of effector molecules, such as polysaccharide A,
and their transportation, for example in OMVs, to enterocytes provides an explanation for host-microbe
interaction in distance without direct physical interaction [61]. In the intestine, bacterial OMVs can also
travel through the thick mucus layer and even through the intestinal epithelial layer. As an example,
OMVs secreted by B. thetaiotaomicron have been found localized in the host immune cells in the
intestinal mucosa [62]. Moreover, B. vulgatus has been shown to modulate immune cells by producing
OMVs, which diffuse through the mucin layer and induce tolerance in dendritic cells in a TLR4 and
TLR2 dependent manner [49]. Besides bacterial effector molecules, short-chain fatty acids (SCFAs)
produced by bacteria can regulate the release of LPS-induced IL-8 from epithelial cells [63].
The identification of bacterial effector molecules responsible for exerting anti-inflammatory action
in the gut still remains an open question. We searched the genomes of our Bacteroides and Parabacteroides
isolates for wcfR gene, which is needed for the synthesis of ZPS (e.g., PSA), but only identified the
homologue in the genome of the B. fragilis isolate. Interestingly, we discovered B. thetaiotaomicron spt gene
(BT_0870) homologues with a significant similarity in the genomes of B. caccae, B. intestinalis, B. fragilis
and B. ovatus. The spt gene is involved in the synthesis of sphingolipids, which mediate bacteria-host
interactions with the help of bacterial OMVs [64]. Bacteroides species are known sphingolipid producers
in the human intestinal tract but to what extent they contribute to the gut homeostasis still remains to be
solved. Colonization of germ-free mice with sphingolipid-deficient B. thetaiotaomicron led to intestinal
inflammation and altered ceramide pools, suggesting that bacterial sphingolipids have a major effect
on intestinal homeostasis [24].
Bacteroides and Parabacteroides spp. are Gram-negative bacteria containing LPS, which is known as
a potent endotoxin that induces a strong pro-inflammatory reaction in the host. However, Bacteroides LPS
has profoundly different properties than the more toxic LPS of Enterobacteriaceae, including E. coli [65].
The lipid A moiety in the LPS structure is responsible for its degree of endotoxicity affecting the ligand
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affinity to TLR4-MD2 complex and downstream activation of the NF-kB pathway [66]. Bacteroides species
seem to possess under-acylated, less toxic lipid A structures based on mass spectrometry analysis
which showed the presence of penta- and tetra-acylated lipid A forms, whereas E. coli possesses the
highly pro-inflammatory, hexa-acylated lipid A domain [65]. Our WGS analysis showed that Bacteroides
and Parabacteroides isolates of this study lack the genes for LpxL and LpxM needed to construct
a hexa-acylated lipid A. On the contrary to the pro-inflammatory form of E. coli LPS, the LPS of
Bacteroides species is immunosuppressive [65,67]. Indeed, Bacteroides LPS has been shown to modulate
the response of primary human peripheral blood mononuclear cells (PBMCs) to E. coli LPS stimulation
by reducing the production of proinflammatory cytokines, such as TNF-a and IL-6 [65]. Moreover,
weak agonistic Bacteroides LPS was shown to have inflammation-reducing properties by ameliorating
inflammatory immune responses in an experimental colitis mouse model [68]. Thus, Bacteroides LPS
may be in part responsible for the anti-inflammatory properties observed in this study.
Bacteroidales spp., such as Alistipes onderdonkii, B. fragilis and B. thetaiotamicron, were shown in
monocolonised mice to maintain intestinal homeostasis by promoting intraepithelial lymphocytes (IEL)
in the colon [51]. IL-6 secretion by IELs is involved in promoting barrier function and requires bacterial
MyD88 signaling. The Bacteroidales species increased IL-6 production in IELs in vivo compared to
an E. coli control, yet only with B. thetaiotamicron was the increase significant. Furthermore, B. fragilis
and B. ovatus were shown to relieve LPS-induced inflammation in a mouse model by decreasing TNF-α
and increasing IL-10 cytokines as well as restoring the Treg/Th17 balance [58]. Promising results
concerning the effectiveness of bacteriotherapy in treating IBD were acquired in a recent study by
Ihekweazu et al. (2019) where B. ovatus monotherapy ameliorated colitis in a murine model and
enhanced epithelial recovery more effectively than traditional FMT [19]. The potential of novel isolates
to exert anti-inflammatory action in vivo remains to be addressed, but the results from previous
studies seem encouraging in this respect. The commensal Bacteroides and Parabacteroides isolates
with anti-inflammatory and epithelium enhancing capacity of this study are potential candidates
concerning bacteriotherapeutic applications aiming to restore the gut homeostasis. The epithelium
reinforcing action of the isolates was shown to enhance Caco-2 monolayer integrity as compared to
medium. However, the isolates capacity to protect against detrimental effects of external factors on the
epithelial integrity or to restore the integrity after an insult was not studied and could be addressed in
future studies.
In conclusion, we developed a high-throughput screening method to isolate bacterial strains
exerting anti-inflammatory capacity in vitro. In this study we isolated from a healthy fecal donor
Bacteroides and Parabacteroides species with capacity to alleviate E. coli LPS-induced IL-8 production
from enterocytes and enhance the epithelial monolayer integrity. Neither of these attributes correlated
with the adhesion ability of the isolates, yet the attenuation capacity sustained when spent medium
from isolates was used suggests that the anti-inflammatory competence is independent of a cell-cell
contact between the bacterium and epithelium. In future studies, we aim to identify potential effector
molecules involved and study the role of OMVs in their anti-inflammatory capacity, for which the
acquired WGS data provide an ideal starting point. The potential of bacteriotherapy for the treatment
of different conditions is becoming more evident, thus underlining the importance of identifying
anti-inflammatory commensals, such as Bacteroides spp., and their effector molecules.
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